Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Qianjiang Yongan Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the production of generic and specialty drugs, particularly in the cardiovascular and anti-infective segments. The company operates primarily in China, leveraging its extensive distribution network and regulatory knowledge to navigate the complex healthcare landscape.
Qianjiang Yongan generates revenue through the sale of generic and specialty pharmaceuticals, capitalizing on its ability to produce cost-effective alternatives to branded drugs. The company benefits from a strong regulatory framework that allows it to quickly bring products to market, alongside a robust distribution network that enhances its reach across various healthcare channels.
Regulatory approvals for new generic drugs
Market share changes in the cardiovascular segment
Pricing pressures from competitors
Changes in healthcare policies affecting drug reimbursement
Regulatory changes that could impact drug approval processes
Technological disruption in drug manufacturing
Increased competition from domestic and international generic manufacturers
Potential price wars in the generic drug market
Low return on equity indicating potential inefficiencies
Limited financial flexibility due to low margins
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Interest rates have minimal direct impact on Qianjiang Yongan's operations due to its low debt levels, but rising rates could affect consumer spending on healthcare products.
minimal
value - Investors may be drawn to the stock due to its low valuation metrics despite recent performance challenges.
high - The stock has exhibited significant volatility, with a 1-year return of -51.7%.
